Astraeus, an investigational study into a potential oral treatment for Alpha-1 lung disease, is currently active and recruiting in the UK. There are seven different trial sites in England and one in Scotland.

EARCO has a global vision to increase the early diagnosis of Alpha-1 antitrypsin deficiency (AATD), understand better the natural history of the disease and ensure optimal access to effective care, placing emphasis on ambitions that serve collective needs of the AATD research community and bringing people with AAT deficiency to the centre of the research environment in a real-world context.


Further information on research in AATD coming soon.